Attached files
file | filename |
---|---|
EX-99 - ADDITIONAL EXHIBITS - Bionik Laboratories Corp. | pressrelease-chinesejvbio.htm |
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, DC 20549
|
|
FORM 8-K
|
CURRENT REPORT PURSUANT
|
TO SECTION 13 OR 15(D) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
Date of
report (Date of earliest event reported): May 24, 2017
|
BIONIK
LABORATORIES CORP.
|
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
000-54717
|
|
27-1340346
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (416) 640-7887
|
||
|
||
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
|
|
Emerging
growth company ☐
|
|
|
|
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Item 7.01
|
Regulation FD Disclosure
|
On May
24, 2017, Bionik Laboratories Corp. (the “Registrant”)
issued a press release announcing that it has established a joint
venture with Ginger Capital Investment Holding Ltd. (“Ginger
Capital”) to bring its evidence-based interactive robotic
systems to the Chinese market, and that Ginger Capital is investing
$500,000 directly into the Registrant through a convertible loan
and $1,450,000 into the joint venture to fund the joint
venture’s operations in China.
A copy
of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The
information in this report (including Exhibit 99.1) is being
furnished pursuant to Item 7.01 and shall not be deemed to be
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed
an admission as to the materiality of any information herein
(including Exhibit 99.1).
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
Exhibit
|
|
Description
|
99.1
|
|
Press Release
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: May 24, 2017
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
|
By:
|
/s/
Peter
Bloch
|
|
Name:
|
Peter
Bloch
|
|
Title:
|
Chairman
and Chief Executive Officer
|